Autolus Therapeutics plc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Autolus Therapeutics plc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $10.12M | Mar 20, 2025 |
| FY2024 | Dec 31, 2023 | $1.70M | Mar 20, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.39M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $10.12M | Mar 27, 2026 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($287.53M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($220.66M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($208.38M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($45.85M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | ($45.55M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | ($39.81M) | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | ($148.84M) | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | ($42.77M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | ($42.06M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | ($37.06M) | Mar 21, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($270.54M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($241.43M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($179.70M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($42.91M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | ($44.38M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | ($39.15M) | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | ($143.41M) | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | ($37.35M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | ($39.06M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | ($36.19M) | Mar 21, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $117.69M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $138.44M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $130.48M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $32.32M | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | $33.23M | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | $27.39M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $117.35M | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | $31.49M | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | $30.79M | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | $28.37M | Mar 21, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $131.87M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $101.72M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $46.75M | Mar 20, 2025 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($283.57M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($206.27M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($145.59M) | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | ($112.31M) | Mar 21, 2024 |
| FY2023 | Dec 31, 2021 | ($117.86M) | Mar 21, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.04M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $22.08M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $10.99M | Mar 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.84M | Mar 21, 2024 |
| FY2023 | Dec 31, 2021 | $8.86M | Mar 21, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $589.07M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $782.73M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $375.38M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $406.10M | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | $450.99M | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | $459.97M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $490.27M | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | $263.83M | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | $313.98M | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | $363.99M | Mar 21, 2024 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $410.94M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $355.40M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $263.91M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $225.58M | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | $221.66M | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | $193.05M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $191.60M | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | $102.68M | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | $99.46M | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | $92.85M | Mar 21, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $178.13M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $427.33M | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $111.47M | Mar 27, 2026 |
| FY2023 | Sep 30, 2023 | $180.52M | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | $229.34M | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | $266.92M | Mar 21, 2024 |
| FY2024 | Dec 31, 2022 | $298.67M | Mar 20, 2025 |
| FY2023 | Sep 30, 2022 | $161.15M | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | $214.52M | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | $271.14M | Mar 21, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.39B) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.10B) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($878.56M) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | ($801.39M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | ($755.54M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | ($709.99M) | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | ($670.18M) | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | ($643.23M) | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | ($600.46M) | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | ($558.40M) | Mar 21, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $104.13M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $227.38M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $239.57M | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | $256.42M | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | $307.50M | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | $343.03M | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | $382.44M | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | $163.05M | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | $216.44M | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | $268.56M | Mar 21, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 21, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 20, 2025 |
| FY2023 | Sep 30, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Jun 30, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Mar 31, 2023 | 0 | Mar 21, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Mar 21, 2024 |
| FY2023 | Sep 30, 2022 | 0 | Mar 21, 2024 |
| FY2023 | Jun 30, 2022 | 0 | Mar 21, 2024 |
| FY2023 | Mar 31, 2022 | 0 | Mar 21, 2024 |